The popularity of Sildenafil initially fueled a period of growth for the drug industry, nevertheless recent shifts present a murky scenario for shareholders. Off-patent versions are eating into earnings, and persistent patent challenges add additional risk to the landscape. While some companies could still gain from related services, the broader di